Author Archive for: TG

Dresden-based experts in sequence-precise gene repair, Seamless Therapeutics, have secured a heavyweight partner. The company has entered into a global research collaboration with the world’s largest pharmaceutical company by market cap, Eli Lilly, to apply its technology platform of specific recombinases to the development of gene therapies for hearing loss. For Seamless, the collaboration could generate total funding of up to USD 1.1 billion if milestones are successfully achieved.

The transatlantic venture firm Epidarex Capital has reached a first close of more than $145 million (approximately €121.6 million) to focus on company creation and early-stage investments across the UK and the US.

At a strategy retreat of the city’s political leadership, the governing parties of the City of Vienna agreed to build a new Life Science Center for Vienna – with the new AI institute AITHYRA as its anchor tenant. To this end, funding of €170 million has been approved, allowing planning to begin.

UK biotech is heading into 2026 with a growing sense of momentum, even as the sector continues to navigate one of the most selective investment climates in years.

Unexpected changes at the top of Rentschler Biopharma: CEO Benedikt von Braunmühl and the Supervisory Board agreed on a swift separation in January, and COO Christiane Bardroff is also set to leave the biopharma manufacturer based in Laupheim, Baden-Württemberg, in the near future. The message from within the company: stay calm, it won´t knock us off course.